Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | PLEC | Q15149 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 10/20 | 0.44 |
| ▸ | CA1 | P00915 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CDC25C | P30307 | 1/20 | 0.44 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352834 | 1.00 | USP2 (0.56) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL3728723 | 0.88 | USP2 (0.57) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL799734 | 0.86 | USP2 (0.62) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL30179280 | 0.86 | USP2 (0.62) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL14007764 | 0.84 | USP2 (0.47) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL25112395 | 0.84 | USP2 (0.64) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL12295575 | 0.84 | USP2 (0.63) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL29415506 | 0.83 | USP2 (0.56) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL2054802 | 0.83 | USP2 (0.56) | USP2MEN1KMT2APOLBATM | |
| SCHEMBL31327372 | 0.83 | USP2 (0.50) | USP2MEN1KMT2APOLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2019-05-16 | — | — | US | disclosed |
| US-10221190-B2 | Biguanide compounds and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | disclosed |
| US-20040054195-A1 | Fluorescent dyes; photostability; labels, staining; analysis | NORTHEASTERN UNIVERSITY | 2004-03-18 | — | — | US | disclosed |
| WO-2002055512-A1 | XANTHENE DERIVATIVES | NORTHEASTERN UNIVERSITY (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | USP2 4532/4885MEN1 351/4885KMT2A 3654/4885 |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | USP2 4532/4885MEN1 351/4885KMT2A 3654/4885 |
| US-10221190-B2 | Biguanide compounds and use thereof | GCKR, GCG, SLC5A2 | USP2 4532/4885MEN1 351/4885KMT2A 3654/4885 |
| US-20040054195-A1 | Fluorescent dyes; photostability; labels, staining; analysis | ANXA5, XDH, TFEB | USP2 3336/4885MEN1 3465/4885KMT2A 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.